MAR 0 6 2003

DOCKET NO. C01037.70017.00S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DApplicant(s):

Bratzler et al.

Serial No.:

09/800,266

Conf. No.:

3753

Filed:

March 5, 2001

For:

IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER

MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT OF

CANCER

Examiner:

Angell, Jon E.

Art Unit:

1635

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

The undersigned hereby certifies that this document is being placed in the Upited States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the day of February, 2003.

Maria A. Trevisan

Commissioner for Patents Washington, D.C. 20231

Sir:

RECEIVED

MAR 1 2 7003

TECH CENTER 1600/2900

Transmitted herewith are the following document(s):

- [x] Amendment
- [x] Appendices A, B, C and D (data and cited references)
- [x] Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

A check in the amount of \$930.00 is enclosed to cover the extension fee. Please charge any fee deficiencies that may be necessitated by this filing to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,

Maria A. Trevisan, Reg. No.: 48,207

WOLF, GREENFIELD & SACKS, P.C.

600 Atlantic Avenue

Boston, MA 02210-2211

(617)720-3500

Docket No.: C01037.70017.US

Date: February X, 2003

X02.28.03

DOCKET NO. C01037.70017.US

#11/ K.T.

TES PATENT AND TRADEMARK OFFICE

Applicant(s):

Bratzler et al. 09/800,266

Serial No.: Conf. No.:

3753

Filed: For:

March 5, 2001

IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT OF

CANCER

Examiner:

Angell, Jon E.

Art Unit:

1635

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 28 day of February, 2003.

RECEIVED

Commissioner for Patents Washington, D.C. 20231

MAR 1 2 2003

TECH CENTER 1600|2900

Sir:

RESPONSE

This is a Response to the Office Action mailed from the United States Patent and Trademark Office on August 28, 2002. A three month extension of time to and including February 28, 2003 for responding is respectfully requested, and the appropriate fee is submitted herewith.

Remarks

Claims 1-17, and 31 are pending. Claims 21 and 36 pertain to a non-elected invention and are cancelled herewith.

Rejection of Claims Under 35 U.S.C. §112, first paragraph

Claims 1-17 and 31 are rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to make and/or use the invention. Applicants respectfully traverse the rejection.

The standard for enablement is whether undue experimentation would be required for one of ordinary skill in the art to practice the claimed invention. To determine whether

03/10/2003 RHARIS1 00000027 09800266